Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

  • STATUS
    Recruiting
  • days left to enroll
    84
  • participants needed
    32
  • sponsor
    Calgent Biotechnology Co., Ltd
Updated on 23 March 2022

Summary

This is a multi-center, open-label, dose-escalation, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics of CAL056 mesylate in cancer patients with resistant or refractory solid tumors.

Description

Patients with resistant or refractory malignant solid tumors and no standard treatment available will be screened for the eligibility. Patients will be screened within 28 days prior to the first dose of CAL056 mesylate. Eligible patients will receive CAL056 mesylate daily with the assigned dose level for 28 days (Day 1 to Day 28) for each treatment cycle. Patients will be administered with CAL056 mesylate at clinical site at scheduled visits (i.e. Day 1/Visit 1, Day 8/Visit 2, Day 15/ Visit 3, Day 22/Visit 4, Day 28/Visit 5). Remaining doses of CAL056 mesylate on all other days will be self-administered by patients at home. After the administration of CAL056 mesylate on Day 1 and Day 28, patients can stay at the clinical site for 24 hours to have safety monitoring and blood samples collected for PK analysis.

Only patients completing Cycle 1 without a dose-limiting toxicity (DLT) or disease progression will be allowed to continue the subsequent cycles at the same dose level. The maximum number of dosing cycle is 6 cycles in each patient in this study. Continuation of using CAL056 mesylate may be permitted after the evaluation of the risk/benefit in individual patient by the Investigators and with the approval of Calgent.

During the Cycle 1 of study period, a total of 5 visits are scheduled to evaluate the safety, PK, preliminary efficacy, and pharmacodynamics of CAL056 mesylate. Each visit is planned on Day 1 of each subsequent cycle if patients continue the treatment of CAL056 mesylate. After the end treatment of CAL056 mesylate, an end of treatment (EOT) visit and a safety follow-up visit will be scheduled.

Details
Condition Resistant or Refractory Solid Tumors
Treatment CAL056 mesylate
Clinical Study IdentifierNCT04686383
SponsorCalgent Biotechnology Co., Ltd
Last Modified on23 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with age ≥ 18 years old
Patients with resistant or refractory solid tumors confirmed by histology which are unresponsive to standard therapies
Patients with at least one measurable lesion per RECIST version 1.1
Patients with Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤ 2
Patients with at least 3 months of life expectancy as judged by the investigators
Patients with adequate bone marrow reserve and organ function
Patients with the negative result for testing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Female patients are eligible to participate if they are of non-childbearing potential or have documentation of a negative serum pregnancy test at screening. Sexually active pre-menopausal women of childbearing potential must agree to use adequate, highly effective contraceptive measures during and upon completion of the study and for at least 6 months after the last dose of study drug
Male patients who agree to use an adequate method of contraception during and upon completion of the study and for at least 6 months after the last dose of study drug
Patients must be willing and be able to provide written informed consent for the study

Exclusion Criteria

History of other invasive malignancy that is currently active and/or has been treated within 12 months prior to screening
Patients with the presence of symptomatic central nervous system (CNS) metastases requiring radiation treatment, surgery, or continuous use of corticosteroids or patients with untreated or developing brain metastasis causing any symptoms, such as neurologic deficits, seizures, or headache
Any prior adjuvant cytotoxic chemotherapy within 4 weeks prior to screening
Any radiotherapy within 2 weeks prior to screening
Pre-existing chemotherapy-related peripheral neuropathy
Currently participating or has participated in a study of an investigational product within 4 weeks prior to the first dose of CAL056 mesylate
Patients with history of organ or stem cell transplant requiring immunosuppressive medications
Active autoimmune disease
Pulmonary conditions such as sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or hypersensitivity pneumonitis
Patients who have chronic obstructive pulmonary disease (COPD) or asthma
Has a history of pneumonitis that required steroids or current pneumonitis
Known significant liver disease
Known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibodies)
Has received live attenuated vaccination within 30 days prior to the first dose of CAL056 mesylate
Female patients who is pregnant, breast-feeding, or planning to become pregnant
Patients with corrected QT interval (QTc) interval of > 450 msec
Has history of clinically significant or severe gastrointestinal disease or condition that may affect drug absorption within the past 3 months
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note